|
WO2020257429A1
|
|
Ectonucleotidase inhibitors and methods of use thereof
|
|
BR112020025132A2
|
|
ectonucleotidase inhibitors and methods of using them
|
|
WO2019089952A1
|
|
Conjoint therapy with glutaminase inhibitors
|
|
SG10201912946TA
|
|
Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
|
|
AU2018231058A1
|
|
Combination therapy with glutaminase inhibitors
|
|
SG10201911243WA
|
|
Compositions and methods for inhibiting arginase activity
|
|
EP3558998A1
|
|
Ectonucleotidase inhibitors and methods of use thereof
|
|
TW201828959A
|
|
Arginase inhibitor combination therapies
|
|
WO2018049145A1
|
|
Ectonucleotidase inhibitors and methods of use thereof
|
|
US2018055843A1
|
|
Combination therapy with glutaminase inhibitors
|
|
WO2018039442A1
|
|
Treatment of cancer with inhibitors of glutaminase
|
|
CN109982703A
|
|
With the combination treatment of glutamine enzyme inhibitor
|
|
SG10201911406TA
|
|
Compositions and methods for inhibiting arginase activity
|
|
WO2017062354A1
|
|
Combination therapy with glutaminase inhibitors and immuno-oncology agents
|
|
EP3313410A1
|
|
Compositions and methods for inhibiting arginase activity
|
|
CN107949387A
|
|
With glutamine ihibitors for treatment lung cancer
|
|
SG11201708034SA
|
|
Methods of administering glutaminase inhibitors
|
|
AU2015300825A1
|
|
Crystal forms of glutaminase inhibitors
|
|
WO2016014890A1
|
|
Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
|
|
AU2015274361A1
|
|
Combination therapy with glutaminase inhibitors
|
